Navigation Links
AGA Medical Corporation Responds to Occlutech Statement on the Status of the Ongoing Patent Litigation in Europe
Date:2/8/2008

MINNEAPOLIS, Feb. 8 /PRNewswire/ -- AGA Medical today issued the following response to a press release distributed on February 7, 2008 regarding a purported victory Occlutech GmbH had achieved in the AIPPI in AGA's patent dispute with Occlutech. The release suggested that a proceeding of some sort was conducted before the AIPPI and that organization agreed with the Occlutech position. That suggestion is false and misleading. AGA has not been involved in any proceedings with Occlutech in which AIPPI has been involved. AIPPI has not contacted AGA for its comments on any matter.

According to its charter, AIPPI is characterized as a trade and professional association and not an adjudicatory body. AIPPI does not seem to engage in any arbitration work. AIPPI is not the "European International Association for the Protection of Intellectual Property" as Occlutech claims, but is simply the International Association for the Protection of Intellectual Property, having no connection with any European governmental entity.

The facts are as follows: after being found to be an infringer of AGA's patent in Germany, Occlutech has made two attempts to stay enforcement in Germany, both of which were unsuccessful. They made an unsuccessful attempt to obtain a ruling of non-infringement/invalidity in Italy that did not succeed. In addition, Occlutech has been found guilty of violating the Court order on infringement in Germany and was fined by the court. The injunction of the German court remains in place.

Additionally, AGA Medical is exploring remedies under German law that might be available to prevent such misrepresentations from continuing.

ABOUT AGA MEDICAL: AGA Medical Corporation, based in Plymouth, Minnesota (just outside Minneapolis) is the leader in developing interventional devices to treat structural heart defects. As a result of the many contributions and creative genius of Dr. Kurt Amplatz, the Company has developed and commercializes a series of devices that have revolutionized the treatment of the most common congenital "holes in the heart" such as atrial septal and patent foramen ovale defects. The company is expanding into new areas such as the minimally invasive repair of vascular abnormalities. Over 790 articles have been published in peer reviewed medical publications that support the benefits of AGA Medical devices including improved patient outcomes, reduced length of stay and accelerated recovery times for the patient, AGA Medical devices have received regulatory approval and are marketed in over 100 countries with over 278,000 devices shipped to date. For more information visit http://www.amplatzer.com.

MEDIA CONTACT:

Devin Nagy

Brunswick Group LLC

202.393.7337

dnagy@brunswickgroup.com


'/>"/>
SOURCE AGA Medical Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Alynx, Co. Completes Merger With Medical Device Company MiMedx, Inc.
2. BioMS Medical to present at BIO CEO & Investor Conference
3. Tutogen Medical, Inc. Reports First Quarter Fiscal 2008 Financial Results
4. Linc Facility Services Acquires Morse Medical
5. Perrigo Company to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
6. Covance to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
7. Blue Cross and Blue Shield of Texas Launches an Integrated Medical-Dental Health Program
8. Tryton Medical Receives CE Mark Approval for its Side-Branch Stent
9. Rochester Medical Reports 31% Increase in Branded Sales Resulting in 9% Overall Sales Growth for the First Quarter
10. Medical University of South Carolina Opens State-of-the-Art Facility
11. Wyeth to Present at the Merrill Lynch 2008 Global Pharmaceutical, Biotechnology and Medical Device Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... , ... CallTower is proud to announce that their hosted Skype ... winner for 2017. , For three consecutive years, CallTower has been recognized by ... awarded with the hosted VoIP Excellence award and in 2015, they received the Skype ...
(Date:1/21/2017)... ... January 21, 2017 , ... Nova Oculus Partners ... a pioneering medical device for the treatment of Age-Related Macular Degeneration. , The ... a global regulatory consultancy that helps companies like ours secure government approvals for ...
(Date:1/21/2017)... 20, 2017 Aratana Therapeutics, Inc. (NASDAQ: ... the licensing, development and commercialization of innovative biopharmaceutical products ... Company in North America 2016. ... based on the FDA approval of three innovative ... ® (capromorelin oral solution) and NOCITA ® ...
(Date:1/20/2017)... January 20, 2017 Stock-Callers.com explores ... have influenced the most recent performances of select equities. ... RGLS ), Abeona Therapeutics Inc. (NASDAQ: ... TBPH ), and Sage Therapeutics Inc. (NASDAQ: ... Grand View Research, global Biotech market size is expected to reach $604.40 ...
Breaking Biology Technology:
(Date:12/22/2016)... YORK , December 22, 2016 ... provider of secure solutions for the e-Government, Public Safety, HealthCare, and ... subsidiary of SuperCom, has been selected to implement and deploy a ... in Northern California , further expanding its presence ... ...
(Date:12/20/2016)... and GENEVA, Dec, 20, 2016   Valencell , ... technology, and STMicroelectronics (NYSE: STM), a global ... electronics applications, announced today the launch of a ... biometric wearables that includes ST,s compact SensorTile ... Benchmark™ biometric sensor system. Together, SensorTile and ...
(Date:12/16/2016)... 2016   IdentyTechSolutions America LLC , a ... solutions and a cutting-edge manufacturer of software and ... offering seamless, integrated solutions that comprise IDT biometric ... solutions provide IdentyTech,s customers with combined physical identification ... crime and theft. "We are proud ...
Breaking Biology News(10 mins):